Scholar Rock Holding (SRRK) Net Cash Flow (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Net Cash Flow of $106.4 million for Q1 2026, up 366.19% year-over-year from $22.8 million in Q1 2025, and up 189.32% quarter-over-quarter from $36.8 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Net Cash Flow (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Net Cash Flow history runs 10 years deep, the most recent figure standing at $106.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 366.19% year-over-year to $106.4 million; the TTM figure through Mar 2026 stood at $293.4 million (up 538.46% YoY), while the FY2025 annual figure was $147.1 million, up 93.43% from the prior year.
- Net Cash Flow for Q1 2026 stood at $106.4 million, up from $36.8 million in the prior quarter.
- The five-year high for Net Cash Flow was $205.6 million in Q2 2022, with the low at -$172.7 million in Q3 2022.
- The 5-year median for Net Cash Flow is $1.4 million (2024), against an average of $12.8 million.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 8912.8% in 2022, then soared 976.74% in 2025.
- Scholar Rock Holding's Net Cash Flow stood at -$29.8 million in 2022, then soared by 214.27% to $34.1 million in 2023, then jumped by 198.04% to $101.5 million in 2024, then sank by 63.78% to $36.8 million in 2025, then soared by 189.32% to $106.4 million in 2026.
- Business Quant data shows SRRK's Net Cash Flow at $106.4 million in Q1 2026, $36.8 million in Q4 2025, and $135.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Scholar Rock Holding | 7.25 Bn | 7.25 Bn | - | 7.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.31 Mn |
| Mar 31, 2026 | 106.35 Mn |
| Dec 31, 2025 | 36.76 Mn |
| Sep 30, 2025 | 135.25 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | -39.95 Mn |
| Dec 31, 2024 | 101.49 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | -9.88 Mn |
| Dec 31, 2023 | 34.05 Mn |
| Sep 30, 2023 | -40.47 Mn |
| Jun 30, 2023 | -43.10 Mn |
| Mar 31, 2023 | 48.01 Mn |
| Dec 31, 2022 | -29.80 Mn |
| Sep 30, 2022 | -172.66 Mn |
| Jun 30, 2022 | 205.56 Mn |
| Mar 31, 2022 | -112.66 Mn |
| Dec 31, 2021 | 36.70 Mn |
| Sep 30, 2021 | -30.79 Mn |